Immunovant Q4 net loss widens to $147.9 million; IMVT-1402 arthritis data shared
Immunovant reported results for the fourth quarter and fiscal year ended March 31, 2026, with its net loss widening as research and development spending rose to $142.3 million in the quarter, including $39.0 million in contractual costs tied to discontinuing batoclimab after two Phase 3 thyroid eye disease studies missed their primary endpoint. The company also shared preliminary open-label Week 16 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis and said its $902.1 million in cash provides runway to a potential Graves' disease launch. For shareholders, the trial data are a positive step, but losses and spending increased, and the results remain preliminary.
Key points
- Net loss for the quarter ended March 31, 2026 was $147.9 million ($0.73 per share), up from $106.4 million ($0.64 per share) a year earlier.
- Full-year net loss was $505.6 million ($2.77 per share), compared with $413.8 million ($2.73 per share) in fiscal 2025.
- IMVT-1402 showed an observed Week 16 ACR20 response rate of 72.7% in 165 evaluable patients in an open-label period; further updates are expected in the second half of calendar 2026.
- Cash and cash equivalents totaled $902.1 million as of March 31, 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.